
# Prestige Consumer Healthcare Inc. PBH

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001295947

**C/D**

**on the C/D boundary of 370 graded peers in healthcare**

rank 216 of 370; percentile 58.3; sampling error 2.5 points; lower is stronger




**C/D, the tortoise**




| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 51.4 |
| **Solvency** | C<br>percentile 46.7 |
| **Growth and financing** | C<br>percentile 54.3 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $3.5B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 12 of 14 |
| **Graded from** | filings received through May 14, 2026<br>168 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $47.79<br>2026-10-28; market equity $2.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received May 14, 2026*

- Major Brands" of this Annual Report on Form 10-K for information regarding market share. We compete for consumers' attention based on a number of factors, including brand recognition, product quality, performance, value to consumers, price and product availability at the retail level. Advertising, marketing, merchandising and packaging and the timing of new product introductions and line extensions also have a significant impact on consumer buying decisions and, as a result, on our market share and our sales. Our markets are highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 51.4** | | | | | | |
| Gross profitability | 17.0% | 32.3% | | 67.9 | 369 | 2026-03-31 |
| Return on invested capital | 8.2% | 9.3% | | 52.1 | 74 | 2026-03-31 |
| Accruals ratio | (2.0%) | (6.6%) | | 76.5 | 805 | 2026-03-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Gross margin stability, five years | 0.8 pts | 2.8 pts | 9.1 | 242 | 2026-03-31 |
| **Solvency, sleeve percentile 46.7** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 4.04 | (0.33) | 21.7 | 751 | 2026-03-31 |
| Net debt to EBITDA | 2.73x | 1.82x | 67.6 | 75 | 2026-03-31 |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2025-03-31; latest annual assets end 2026-03-31* | | | | | |
| Current ratio | 3.57x | 2.94x | 50.8 | 832 | 2026-03-31 |
| **Growth and financing, sleeve percentile 54.3** | | | | | |
| Revenue growth, three-year compound | (1.2%) | 10.1% | 74.3 | 413 | 2026-03-31 |
| Free cash flow growth, three-year compound | 3.6% | 10.9% | 63.2 | 96 | 2026-03-31 |
| Reinvestment rate | (22.4%) | 37.1% | 80.6 | 104 | 2026-03-31 |
| Asset growth, three years | 1.4% | 2.1% | 49.0 | 697 | 2026-03-31 |
| Net share issuance, one year | (4.1%) | 2.5% | 4.6 | 633 | 2026-05-12 |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 211 | Cooper Companies, Inc. (COO) | 56.9 | C | |
| 212 | Perspective Therapeutics, Inc. (CATX) | 57.2 | C | dilution, fortress balance sheet |
| 213 | Cryo Cell International Inc. (CCEL) | 57.5 | C | |
| 214 | electroCore, Inc. (ECOR) | 57.7 | C/D | |
| 215 | Rocket Pharmaceuticals, Inc. (RCKT) | 58.0 | C/D | degenerate inputs |
| 216 | Prestige Consumer Healthcare Inc. (PBH) | 58.3 | C/D | |
| 217 | Tango Therapeutics, Inc. (TNGX) | 58.5 | C/D | dilution |
| 218 | Becton Dickinson & Co. (BDX) | 58.8 | C/D | |
| 219 | Option Care Health, Inc. (OPCH) | 59.1 | C/D | |
| 220 | Cryoport, Inc. (CYRX) | 59.3 | C/D | late filer |
| 221 | Trulieve Cannabis Corp. (TRLV) | 59.6 | C/D | fortress balance sheet |

## What the price implies

*at the 2026-10-28 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (17.0%) | 7.7% | 32 |
| Distance from 52-week high | (31.9%) | (27.7%) | 43 |
| EBIT to enterprise value | 9.8% | (1.5%) | 91 |
| Free cash flow yield | 10.9% | (1.0%) | 92 |
| Book value to price | 0.85 | 0.27 | 82 |
| Sales to price | 0.48 | 0.31 | 66 |
| Composite equity issuance, five years | (5.2%) | 20.5% | 20 |
| Relative strength against the sector, log excess return | (0.40) | (0.14) | 32 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 5 of 9, period end 2026-03-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $89.1M |
| Operating cash flow, four quarters | $249.4M |
| Months of runway | not finite |
| Days since last periodic filing | 84 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $26.5M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $595.6M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 2 | assets | us-gaap:Assets | $3.5B | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $309.4M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $257.5M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $67.2M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 6 | total debt | us-gaap:LongTermDebt | $994.0M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 7 | book equity | us-gaap:StockholdersEquity | $1.9B | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $63.9M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 9 | total debt | us-gaap:LongTermDebt | $992.4M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 10 | book equity | us-gaap:StockholdersEquity | $1.8B | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $97.9M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 12 | net income | us-gaap:NetIncomeLoss | $190.3M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $257.6M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 14 | assets | us-gaap:Assets | $3.4B | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1B | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 16 | gross profit | us-gaap:GrossProfit | $634.5M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1B | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 18 | gross profit | us-gaap:GrossProfit | $624.4M | 2024-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1B | 2024-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 20 | gross profit | us-gaap:GrossProfit | $625.3M | 2023-03-31 | 2025-05-09 | 10-K | 25-000017 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1B | 2023-03-31 | 2025-05-09 | 10-K | 25-000017 |
| 22 | gross profit | us-gaap:GrossProfit | $620.6M | 2022-03-31 | 2024-05-15 | 10-K | 24-000017 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.1B | 2022-03-31 | 2024-05-15 | 10-K | 24-000017 |
| 24 | current assets | us-gaap:AssetsCurrent | $431.5M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $120.9M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $1.7B | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 27 | liabilities | us-gaap:Liabilities | $1.6B | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $31.3M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 29 | operating income | us-gaap:OperatingIncomeLoss | $336.8M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 30 | interest expense | us-gaap:InterestExpense | $1.8M | 2025-03-31 | 2025-05-09 | 10-K | 25-000017 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $11.2M | 2026-03-31 | 2026-05-14 | 10-K | 26-000016 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $251.5M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $8.2M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $248.9M | 2024-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9.6M | 2024-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $229.7M | 2023-03-31 | 2025-05-09 | 10-K | 25-000017 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $7.8M | 2023-03-31 | 2025-05-09 | 10-K | 25-000017 |
| 38 | current assets | us-gaap:AssetsCurrent | $448.3M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $106.6M | 2025-03-31 | 2026-05-14 | 10-K | 26-000016 |
| 40 | assets | us-gaap:Assets | $3.3B | 2024-03-31 | 2025-05-09 | 10-K | 25-000017 |
| 41 | assets | us-gaap:Assets | $3.4B | 2023-03-31 | 2024-05-15 | 10-K | 24-000017 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 47,372,166 | 2026-05-12 | 2026-05-14 | 10-K | 26-000016 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 49,414,707 | 2025-05-01 | 2025-05-09 | 10-K | 25-000017 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.